Overview
MOA
Impact
X
Procedure
Guidelines
Resources
Clinical Library
Reimbursement
Grants
Order Cysview
Overview
White vs. Blue Light
Patient Stories
Bladder Cancer Overview
X
Resources
Home
BLC™ with Cysview®
>
News
Health Care Professionals
>
Find a BLC with Cysview Center
X
Cysview LogoHamburger Menu Icon
Menu
Find a BLC with Cysview Center

Patient
Stories

BLC™ with Cysview®

Patient Stories

Lighting the Way

“Everyone should have access to this technology.”

Mary Beth Ballard was a 28-year-old newlywed with a bright future when she was diagnosed with non-muscle invasive bladder cancer. After a standard white light cystoscopy and transurethral resection of bladder tumor (TURBT), Mary Beth pursued a second opinion from a Blue Light Cystoscopy with Cysview® (BLC™ with Cysview®) provider. They found 60 percent more cancerous cells that had been missed from her initial procedure.

Effective management of your disease starts with accurate detection, and BLC with Cysview delivers unequaled results. Hear more about Mary Beth's experience with BLC with Cysview and why she thinks every bladder cancer patient should have access to BLC with Cysview technology by watching the video above.

In 2018, a patient survey of 550 non-muscle invasive bladder cancer patients was conducted. Their responses illustrate the use of BLC with Cysview affected the way they felt about their disease management and they would seek treatment at centers that offer the procedure. So far, over 440,000 patients around the world have utilized this innovative technology to better control their bladder cancer.14

89%
stated BLC with Cysview improved their confidence in the
treatment they received.14

87%
once diagnosed sought institutions that offered BLC with Cysview.14

95% 
confirmed the importance of having BLC with Cysview as part of their disease management.14

When to Ask Your Doctor
About BLC with Cysview

If you are at any of the above phases in your disease management, find a center that offers Blue Light Cystoscopy with Cysview and talk to your urologist about the technology.

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo

Prescribing Information

Cysview is an optical imaging agent indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLCTM) as an adjunct to the white light cystoscopy.

Important Safety Information About Cysview® (hexaminolevulinate HCl)

Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer. 

Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain. 

Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed. 

Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition. 

Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components. 

Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions.

Photocure Logo
<  PREV  White vs. Blue Light
BACK TO TOP
NEXT  Bladder Cancer Overview  >